Home | Find A Doctor | Contact Us

 

Randomized Phase II 2x2 Factorial Trial Of The Addition of Carboplatin And/Or Bevacizumab To Neoadjuvant Weekly Paclitaxel Followed By Dose-Dense AC In Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer


Principal Investigator: Paula Klein, MD
Time frame of study: Ongoing
Location of Study:

Mount Sinai Beth Israel
St.Luke's-Mount Sinai Roosevelt

Contact:

Continuum Cancer Research Program
(212) 844-6286

 

Summary:
The purpose of the study is to see if adding other drugs to standard neoadjuvant chemotherapy can help shrink triple-negative breast cancer faster, and lower the risk of the cancer coming back in other part of the body.
In addition to studying their effectiveness, the study is designed to find out how frequently patients have side effects from these treatments. We are also studying a number of biologic characteristics in the cancer cells and blood of patients like you to see whether those characteristics predict which patients are more likely to achieve a pCR and which patients may benefit from the addition of carboplatin and/or bevacizumab to the standard treatment regimen.


Eligibility and Treatment Plan:
Age 18 or older
Stage II-III invasive breast cancer with intent to perform surgical resection after neoadjuvant therapy
Invasive tumor must be hormone receptor-poor and HER2-negative
Patient must agree to undergo pretreatment research biopsies.

Please call for more information.

 

 

Privacy Policy | Site Map
Copyright ©  Icahn School of Medicine at Mount Sinai | Mount Sinai Health System